- Home
- LPTX vs PRTS Comparison
LPTX vs PRTS Comparison
Compare LPTX & PRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- PRTS
- Stock Information
- Founded
- LPTX 2011
- PRTS 1995
- Country
- LPTX United States
- PRTS United States
- Employees
- LPTX N/A
- PRTS N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- PRTS Auto & Home Supply Stores
- Sector
- LPTX Health Care
- PRTS Consumer Discretionary
- Exchange
- LPTX Nasdaq
- PRTS Nasdaq
- Market Cap
- LPTX 35.4M
- PRTS 40.0M
- IPO Year
- LPTX N/A
- PRTS 2007
- Fundamental
- Price
- LPTX $0.42
- PRTS $0.68
- Analyst Decision
- LPTX Hold
- PRTS Hold
- Analyst Count
- LPTX 1
- PRTS 1
- Target Price
- LPTX N/A
- PRTS $0.70
- AVG Volume (30 Days)
- LPTX 7.1M
- PRTS 630.1K
- Earning Date
- LPTX 11-13-2025
- PRTS 11-10-2025
- Dividend Yield
- LPTX N/A
- PRTS N/A
- EPS Growth
- LPTX N/A
- PRTS N/A
- EPS
- LPTX N/A
- PRTS N/A
- Revenue
- LPTX N/A
- PRTS $577,614,000.00
- Revenue This Year
- LPTX N/A
- PRTS N/A
- Revenue Next Year
- LPTX N/A
- PRTS $2.62
- P/E Ratio
- LPTX N/A
- PRTS N/A
- Revenue Growth
- LPTX N/A
- PRTS N/A
- 52 Week Low
- LPTX $0.22
- PRTS $0.64
- 52 Week High
- LPTX $4.24
- PRTS $1.42
- Technical
- Relative Strength Index (RSI)
- LPTX 42.80
- PRTS 45.47
- Support Level
- LPTX $0.43
- PRTS $0.67
- Resistance Level
- LPTX $0.56
- PRTS $0.71
- Average True Range (ATR)
- LPTX 0.06
- PRTS 0.03
- MACD
- LPTX -0.02
- PRTS 0.01
- Stochastic Oscillator
- LPTX 0.04
- PRTS 34.09
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.
About PRTS CarParts.com Inc.
CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. It serves as an end-to-end solution for automotive repair and maintenance resources, offering a seamless online shopping experience that empowers drivers along every part of their journey. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.